High-Accuracy Height-Independent 3D VLP Based on Received Signal Strength Ratio.

Visible light positioning (VLP) has attracted intensive attention from both academic and industrial communities thanks to its high accuracy, immunity to electromagnetic interference, and low deployment cost. In general, the receiver in a VLP system determines its own position by exploring the received signal strength (RSS) from the transmitter according to a pre-built RSS attenuation model. In such model-based methods, the LED's emission power and the receiver's height are usually required known and constant parameters to obtain reasonable positioning accuracy. However, the LED's emission power is normally time-varying due to the fact that the LED's optical output power is prone to changing with the LED's temperature, and the receiver's height is random in a realistic application scenario. To this end, we propose a height-independent three-dimensional (3D) VLP scheme based on the RSS ratio (RSSR), rather than only using RSS. Unlike existing RSS-based VLP methods, our method is able to independently find the horizontal coordinate, i.e., two-dimensional (2D) position, without a priori height information of the receiver, and also avoids the negative effect caused by fluctuation of the LED's emission power. Moreover, we can further infer the height of the receiver to achieve three-dimensional (3D) positioning by iterating the 2D results back into positioning equations. To quickly verify the proposed scheme, we conduct theoretical analysis with mathematical proof and experimental results with real data, which confirm that the proposed scheme can achieve high position accuracy without known information of the receiver's height and LED's emission power. We also implement a VLP prototype with five LED transmitters, and experimental results show that the proposed scheme can achieve very low average errors of 2.73 cm in 2D and 7.20 cm in 3D.

Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy.

AIMS: To investigate the roles of CXCL16 and ox-LDL in adriamycin (ADR)-induced nephropathy mice and to explore the mechanism of simvastatin on the renal protective effects of ADR nephropathy. METHODS: Fifteen male Balb/c mice were randomly divided into normal control (NC), ADR nephropathy and simvastatin-treated ADR nephropathy (ADR-SIM) groups. ADR nephropathy was induced by a single intravenous injection of ADR into the tail vein. All mice were sacrificed at the end of the 7th week, with the blood, 24-h urine and kidneys collected. The levels of ox-LDL and total cholesterol in the serum, the serum CXCL16, ox-LDL and NF-κB expression were detected. RESULTS: Compared with the NC group, the levels of serum total cholesterol and ox-LDL in the ADR and ADR-SIM groups were significantly higher, the level of serum albumin was significantly lower and the expression of CXCL16, ox-LDL and NF-κB in the renal tissue of ADR and ADR-SIM groups was significantly increased. Compared with the ADR group, the expressions of renal CXCL16, ox-LDL and NF-κB in the ADR-SIM group were significantly decreased. Levels of serum total cholesterol and ox-LDL were not significantly different between the two groups. CONCLUSIONS: Simvastatin exerts a protective effect on renal function and structure in mice with ADR nephropathy. The beneficial effects of simvastatin might be related to the decreasing expression of CXCL16 in glomerular podocytes followed by the decreasing endocytosis of ox-LDL in podocytes and inhibition of NF-κB pathway activation.